Drug Res (Stuttg) 2015; 65(S 01): S8-S10
DOI: 10.1055/s-0035-1558061
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Therapie der axialen Spondyloarthritis

J. Braun
Rheumazentrum Ruhrgebiet, Herne
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2015 (online)

Spondyloarthritiden (SpA) sind entzündlich rheumatische Erkrankungen mit einigen klinischen und genetischen Gemeinsamkeiten, Überlappungen und Übergängen. Besonders charakteristisch ist die Beteiligung des Achsenskeletts und der Sehnenansätze (Enthesien) sowie die Assoziation mit dem MHC Klasse I Antigen HLA B27. Man unterscheidet auf klinischer und z. T. radiologischer Basis: axiale SpA inkl. der Spondylitis ankylosans (AS), SpA bei Psoriasis bzw. Psoriasisarthritis, reaktive Arthritis (ReA), SpA bei chronisch entzündlichen Darmerkrankungen und undifferenzierte SpA (uSpA). Hinsichtlich der Kombination von Schuppenflechte und Arthritis gibt es parallel auch den Ansatz, in dem sämtliche entzündlich rheumatischen Manifestationen bei Patienten mit Psoriasis als Psoriasisarthritis (PsA) zusammengefasst sind. Eine Sonderform ist das SAPHO-Syndrom (Synovitis, Akne, Pustolose, Hyperostose, Osteitis).

 
  • Literatur

  • 1 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369 (9570) 1379-1390
  • 2 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368
  • 3 Feldtkeller E, Khan MA, van der Heijde D et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61-66
  • 4 Rudwaleit M, Landewé R, van der Heijde D et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770-776
  • 5 Rudwaleit M, van der Heijde D, Landewé R et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. Ann Rheum Dis 2009; 68: 777-783
  • 6 Kiltz U, Baraliakos X, Karakostas P et al. Patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis in several aspects. Arthritis Care Res (Hoboken) 2012; Apr 13 [Epub ahead of print]
  • 7 Mau W, Zeidler H, Mau R et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988; 15: 1109-1114
  • 8 Rudwaleit M, Haibel H, Baraliakos X et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60: 717-727
  • 9 Poddubnyy D, Rudwaleit M, Haibel H et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 1369-1374
  • 10 van den Berg R, de Hooge M, van Gaalen F et al. Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology (Oxford) 2013; 52: 1492-1499
  • 11 Poddubnyy D, Brandt H, Vahldiek J et al. The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Ann Rheum Dis 2012; 71: 1998-2001
  • 12 Song IH, Weiß A, Hermann KG et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013; 72: 823-825
  • 13 Landewé R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2013; Sep 6 [Epub ahead of print]
  • 14 van der Heijde D, Sieper J, Maksymowych WP et al. for the Assessment of SpondyloArthritis international Society 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-908
  • 15 Calin A, Porta J, Fries JF et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237: 2613-2614
  • 16 Rudwaleit M, Metter A, Listing J et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54: 569-578
  • 17 Braun J, Inman R. Inflammatory back pain. Ann Rheum Dis 2010; 69: 1264-1268
  • 18 Braun J, Sieper J. Classification, diagnosis, and referral of patients with axial spon-dyloarthritis. Rheum Dis Clin North Am 2012; 38: 477-485
  • 19 Braun J, Baraliakos X, Kiltz U. Non-radiographic axial spondyloarthritis: a classification or a diagnosis?. Clin Exp Rheumatol 2015; Apr 17 [Epub ahead of print]
  • 20 Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344 (8930) 1105-1110
  • 21 van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohnʼs disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
  • 22 Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356 (9227) 385-390
  • 23 Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505
  • 24 Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-1352
  • 25 Van den Bosch F, Kruithof E, De Vos M et al. Crohnʼs disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356 (9244) 1821-1822
  • 26 Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313) 1187-1193
  • 27 Gorman JD, Sack KE, Davis Jr. JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-1356
  • 28 Dougados M, van der Heijde D, Sieper J et al. The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2014; May 28 [Epub ahead of print]
  • 29 Sieper J et al. Arthritis Rheumatol 2015 in press.
  • 30 Braun J et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63: 1543-1551
  • 31 Braun J et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012; 71: 661-667
  • 32 Braun J et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. Ann Rheum Dis 2011;
  • 33 Callhoff J, Sieper J, Weiß A et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015; 74: 1241-1248
  • 34 Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 1126-1136
  • 35 Baraliakos X, Haibel H, Listing J et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73: 710-715
  • 36 Vastesaeger N, van der Heijde D, Inman RD et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011; 70: 973-981
  • 37 Braun J et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904
  • 38 Smolen JS, Braun J, Dougados M et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73: 6-16
  • 39 Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12
  • 40 Kiltz U, Baraliakos X, Karakostas P et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 2012; 71: 1207-1211
  • 41 Poddubnyy D, Hermann KG, Callhoff J et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014; 73: 817-823
  • 42 Baeten D, Baraliakos X, Braun J et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382 (9906) 1705-1713